BioNTech pays $170M to add would-be Enhertu rival to pipeline – FierceBiotech

by

  1. BioNTech pays $170M to add would-be Enhertu rival to pipeline FierceBiotech
  2. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors GlobeNewswire
  3. BioNTech to pay $170M upfront in license deal for 2 cancer drug Seeking Alpha
  4. BioNTech, DualityBio Ink Up-to-$1.7B Cancer ADC Collaboration Genetic Engineering & Biotechnology News
  5. BioNTech, DualityBio to develop cancer treatment drugs in over $1.5-bln deal Reuters
  6. View Full Coverage on Google News

Read original article here

Leave a Comment